New clinical trial data from HYPERION are now included in Winrevair’s label, which also adds a contraindication for serious ...

Gossamer Bio submitted an FDA application for approval of seralutinib, an inhaled therapy for adults with pulmonary arterial ...

People newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) who have lower exercise capacity and poorer breathing efficiency during exercise tend to also report more severe ...

After five years of raising rare disease awareness, columnist Anna Jeter is retiring "Blooming Hope" and says farewell to her ...

Pulmonary hypertension (PH) is caused by high blood pressure in the lungs, which is caused by narrowed and thickened pulmonary arteries. Because of the added effort needed to pump blood through the ...

Pulmonary hypertension (PH) is high blood pressure in the pulmonary arteries, which carry blood from the right side of the heart to the lungs. Current estimates suggest a prevalence of PH of about 1% ...

What is Winrevair for pulmonary arterial hypertension? Winrevair (sotatercept-csrk) is an injection therapy for adults with pulmonary arterial hypertension (PAH), approved in the U.S. to improve ...

Although there is no cure yet for pulmonary hypertension (PH), there are a variety of therapies available that can help manage the symptoms of the disease and maintain or improve the quality of life ...

[vc_row][vc_column][vc_column_text]Pulmonary hypertension (PH) is a rare but severe disease characterized by high blood pressure in the lungs. The disease affects the pulmonary arteries, which are ...

Pulmonary hypertension (PH) is a rare but severe condition characterized by high blood pressure that affects pulmonary arteries – the vessels responsible for transporting blood from the heart to the ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google Chronic kidney disease (CKD) is common among people newly ...